Chemours Company (CC) AI Stock Analysis

• Market Cap: $1.66B
• Dividend Yield: 4.89%
• Average Volume (3M): 3.13M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: 2.12%
• EPS Growth: -579.74%
• Country: US
• Employees: 6,000
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 0.20
• Shares Outstanding: 149,891,950
• 10 Day Avg. Volume: 3,479,882
• 30 Day Avg. Volume: 3,127,162
• PEG Ratio: -0.22
• Price to Book (P/B): 4.18
• Price to Sales (P/S): 0.44
• P/FCF Ratio: -2.54
• Enterprise Value/Market Cap: 3.74
• Enterprise Value/Revenue: 1.05
• Enterprise Value/Gross Profit: 6.06
• Enterprise Value/Ebitda: 9.41
• 1Y Price Target: $16.86
• Price Target Upside: 52.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 1.04
• Revenue Forecast (FY): $5.81B

• Rating: 46 Neutral
• Price Target: $12.50 ▲(13.12% Upside)

Chemours Company is currently facing significant financial and operational challenges. The most impactful factor is the company's weak financial performance, characterized by declining revenue, profitability, and cash flow generation. Technical analysis also indicates bearish momentum, with the stock trading below key moving averages and showing oversold conditions. While the earnings call provided some positive insights, such as strong Opteon sales, these were overshadowed by challenges in other segments. The valuation is mixed, with a negative P/E ratio but a relatively high dividend yield. Overall, the stock score reflects the need for the company to address its operational inefficiencies and improve financial stability.

Positive Factors

Opteon Sales Growth

Strong growth in Opteon sales reflects robust demand and market leadership in refrigerants, supporting long-term revenue stability.

Technical Qualification Success

This qualification enhances Chemours' market position in liquid cooling products, potentially driving future revenue and innovation.

Cost Structure Improvements

Improved cost structure enhances operational efficiency, potentially leading to better margins and financial health over time.

Negative Factors

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting long-term stability and investment capacity.

Negative Cash Flow

Negative cash flow highlights inefficiencies in operations, which can strain resources and hinder growth initiatives.

TT Segment Underperformance

Underperformance in the TT segment suggests vulnerability to market conditions, affecting revenue and profitability.

Chemours Company Business Overview & Revenue Model

Company Description

Chemours Company (CC) is a global leader in the chemical industry, specializing in the production of titanium dioxide, fluoroproducts, and chemical solutions. The company operates in three main segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions, offering a wide range of products that serve various industries including automotive, construction, electronics, and consumer products. Chemours is dedicated to sustainable practices and innovation, providing high-performance materials and solutions that meet the evolving needs of its customers.

How the Company Makes Money

Chemours generates revenue primarily through the sale of its core products across its three business segments. The Titanium Technologies segment is a significant source of income, producing titanium dioxide, which is widely used as a pigment in paints, coatings, and plastics. The Fluoroproducts segment includes a variety of fluorinated products that are essential in refrigeration, air conditioning, and other industrial applications. The Chemical Solutions segment provides custom and specialty chemicals for various applications. Additionally, Chemours has established key partnerships and collaborations within the industry that enhance its market reach and product offerings. The company also focuses on operational efficiency and cost management to bolster its profit margins, contributing to its overall financial performance.

Chemours Company Financial Statement Overview

Summary

Chemours Company is facing financial challenges with declining revenue and profitability, high leverage, and weak cash flow generation. The income statement shows a declining trend in revenue with a negative revenue growth rate of -10.2% in TTM. The balance sheet reveals a high debt-to-equity ratio of 0.86, and cash flow analysis indicates a substantial decline in free cash flow growth at -120% in TTM.

Income Statement

The income statement shows a declining trend in revenue with a negative revenue growth rate of -10.2% in TTM. Gross profit margin has decreased from 21.67% in 2023 to 17.37% in TTM, indicating reduced profitability. The net profit margin is negative at -5.67% in TTM, reflecting a net loss. EBIT and EBITDA margins have also declined, highlighting operational challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 0.86 in TTM, which is an improvement from previous years but still indicates significant leverage. Return on equity is negative at -77.53% in TTM, due to net losses, which is concerning. The equity ratio stands at 3.94%, showing a low proportion of equity financing.

Cash Flow

Cash flow analysis indicates a substantial decline in free cash flow growth at -120% in TTM. The operating cash flow to net income ratio is 0.14, suggesting weak cash generation relative to net income. The free cash flow to net income ratio is low at 2.64%, reflecting limited free cash flow relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.87B	5.78B	6.08B	6.83B	6.34B	4.97B
Gross Profit	1.02B	1.15B	1.31B	1.62B	1.38B	1.07B
EBITDA	658.00M	692.00M	197.00M	1.20B	1.18B	767.00M
Net Income	-333.00M	86.00M	-238.00M	578.00M	608.00M	219.00M
Balance Sheet
Total Assets	7.57B	7.51B	8.25B	7.64B	7.55B	7.08B
Cash, Cash Equivalents and Short-Term Investments	613.00M	713.00M	1.20B	1.10B	1.45B	1.10B
Total Debt	4.42B	4.36B	4.30B	3.88B	3.99B	4.28B
Total Liabilities	7.27B	6.91B	7.51B	6.53B	6.47B	6.27B
Stockholders Equity	298.00M	604.00M	737.00M	1.11B	1.08B	813.00M
Cash Flow
Free Cash Flow	-12.00M	-993.00M	186.00M	448.00M	537.00M	540.00M
Operating Cash Flow	265.00M	-633.00M	556.00M	755.00M	814.00M	807.00M
Investing Cash Flow	-270.00M	-353.00M	-229.00M	-284.00M	220.00M	-234.00M
Financing Cash Flow	-4.00M	-36.00M	172.00M	-686.00M	-554.00M	-449.00M

Chemours Company Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CC, the sentiment is Negative. The current price of 11.05 is below the 20-day moving average (MA) of 12.23, below the 50-day MA of 13.93, and below the 200-day MA of 13.20, indicating a bearish trend. The MACD of -0.82 indicates Positive momentum. The RSI at 35.21 is Neutral, neither overbought nor oversold. The STOCH value of 10.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CC.

Chemours Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
KWR	58 Neutral	$2.21B	―	-0.64%	1.54%	0.08%	-107.33%
ASH	54 Neutral	$2.24B	―	-34.45%	3.40%	-13.67%	―
IOSP	49 Neutral	$1.84B	―	-0.09%	2.37%	-4.49%	-100.80%
OLN	48 Neutral	$2.26B	42.65	2.67%	3.85%	4.68%	-62.80%
NGVT	48 Neutral	$1.74B	―	-38.91%	―	-13.39%	88.25%
CC	46 Neutral	$1.66B	―	-69.74%	4.89%	2.12%	-579.74%

Chemours Company Corporate Events

Chemours Company Reports Stable Q3 2025 Earnings

The Chemours Company is a global leader in the industrial and specialty chemicals sector, providing solutions across various markets such as coatings, plastics, refrigeration, and more, with flagship products under brands like Opteon™ and Teflon™.

Chemours Approves New Executive Severance Policy

On October 28, 2025, The Chemours Company‘s Board of Directors approved a new Executive Severance Policy to provide payments and benefits to executive officers and certain employees upon specified terminations of employment. This policy aims to offer financial security to executives in cases of involuntary termination without cause or resignation for good reason, potentially impacting the company’s operational stability and employee retention strategies.

The most recent analyst rating on (CC) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.

Chemours Extends $1.05 Billion Loan Maturity

On October 15, 2025, Chemours Company amended its credit agreement to extend the maturity date of a $1.05 billion term loan facility to October 15, 2032, and adjusted the applicable margin rates. This move is likely to impact the company’s financial stability positively by providing more time for repayment and potentially reducing interest expenses. Additionally, on October 13, 2025, Chemours’ subsidiaries entered into a Receivables Purchase Agreement with BNP Paribas Factor GmbH, allowing the sale of receivables up to €180 million. This agreement could enhance liquidity for Chemours by converting receivables into immediate cash, thus supporting its operational cash flow.

The most recent analyst rating on (CC) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.

Chemours Appoints New Chair and Lead Director

On September 2, 2025, Chemours Company announced changes in its Board of Directors, appointing Mary Cranston as Chair and Alister Cowan as Lead Independent Director, following Dawn Farrell’s departure to join the Canadian government. These leadership changes are significant for the company’s governance and may influence its strategic direction and stakeholder relations.

The most recent analyst rating on (CC) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.

Chemours Chair Dawn Farrell Resigns for New Role

On August 29, 2025, Dawn Farrell, Chair of the Board of Directors at The Chemours Company, announced her resignation effective September 2, 2025, to take on a new role as Chief Executive Officer of the Major Projects Office under the Canadian government. The company has yet to decide on her successor, signaling a forthcoming announcement regarding the new Chair of the Board.

The most recent analyst rating on (CC) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.